Bioavailability of three novel oral, sustained‐release pellets, relative to an immediate‐release tablet containing 500 mg flucytosine: A randomized, open‐label, crossover study in healthy volunteersVishal Goyal, Isabela Ribeiro, Amit Antarkar et al.|Clinical and Translational Science|2024Cited by 4
Bioavailability of a novel sustained‐release pellet formulation of 5‐flucytosine in healthy‐fed participants for use in patients with cryptococcal meningitisNabila Ibnou Zekri Lassout, Isabela Ribeiro, Vishal Goyal et al.|Clinical and Translational Science|2024Cited by 2
PA-298 Predicting disease effect on the pharmacokinetics (PK) of sustained and immediate release formulations by applying physiologically based pharmacokinetic (PBPK) modellingJohanna Eriksson, Marylore Chenel, Eric B. Sjogren et al.|Unknown|2023Cited by 0
Physiologically based pharmacokinetic modelling to support the development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis: An MIDD case studyJohanna Eriksson, Marylore Chenel, Vishal Goyal et al.|Unknown|2024Cited by 0
Model‐Informed Drug Development of a Sustained Release Formulation of Flucytosine in the Treatment of Cryptococcal Meningitis: A Case Study Using Physiologically Based Pharmacokinetic ModelingJohanna Eriksson, Marylore Chenel, Erik Sjögren et al.|CPT Pharmacometrics & Systems Pharmacology|2025Cited by 0